<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8970">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789191</url>
  </required_header>
  <id_info>
    <org_study_id>NN304-3511</org_study_id>
    <secondary_id>2008-001050-40</secondary_id>
    <nct_id>NCT00789191</nct_id>
  </id_info>
  <brief_title>Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes</brief_title>
  <official_title>Effect of Detemir and Sitagliptin on Blood Glucose Control in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: The Biologics and Genetic Therapies Directorate (BGTD)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Asia, Europe and North America. This trial aims for comparison of
      the effect on the glycemic control in subjects with type 2 diabetes of basal insulin
      analogue with one oral anti-diabetic drug (OAD) versus oral anti-diabetic drug alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HbA1c (Glycosylated Haemoglobin A1c)</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving HbA1c Less Than or Equal to 7.0%</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving HbA1c Less Than or Equal to 7.0% Without Symptomatic Hypoglycaemia</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving HbA1c Less Than or Equal to 6.5%</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving HbA1c Less Than or Equal to 6.5% Without Symptomatic Hypoglycaemia</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI (Body Mass Index)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG (Fasting Plasma Glucose)</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Episodes</measure>
    <time_frame>Weeks 0-26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall: All episodes. Minor: Symptomatic, with PG &lt; 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Episodes: Day Time</measure>
    <time_frame>Weeks 0-26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Day time: Episodes between 6 pm and 11 am. Overall: All episodes. Minor: Symptomatic, with PG &lt; 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Episodes: Night Time</measure>
    <time_frame>Weeks 0-26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Night time: Episodes between 11 am and 6 pm. Overall: All episodes. Minor: Symptomatic, with PG &lt; 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-measured 9-point Plasma Glucose Profile</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Comb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sita</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.</description>
    <arm_group_label>Comb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.</description>
    <arm_group_label>Comb</arm_group_label>
    <arm_group_label>Sita</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.</description>
    <arm_group_label>Comb</arm_group_label>
    <arm_group_label>Sita</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulphonylurea</intervention_name>
    <description>Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.</description>
    <arm_group_label>Sita</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes for at least 6 months before trial start

          -  Treatment with at least 1000 mg metformin per day for at least 3 months

          -  Insulin-naive (short-term insulin treatment of up to 14 days is allowed)

          -  DPP-4 (dipeptidyl peptidase-4) inhibitor naive

          -  HbA1c (glycosylated haemoglobin A1c) between 7.5-10.0% by central laboratory analysis

          -  BMI (Body Mass Index) lesser than or equal to 45.0 kg/m2

          -  Able and willing to take one subcutaneous injection every day

          -  Able and willing to perform mandatory SMPG (self measured plasma glucose)
             measurements

        Exclusion Criteria:

          -  Known or suspected allergy or intolerance to any of the trial products or related
             products

          -  Severe hypertension

          -  Treatment with thiazolidinedione (TZD) or GLP-1 (glucagon-like peptide-1) analogues
             within 2 months prior to trial start

          -  Cardiac disease, within the last 12 months

          -  Impaired hepatic function

          -  Impaired renal function

          -  Proliferative retinopathy or macular oedema requiring acute treatment

          -  Female of childbearing potential

          -  Known or suspected abuse of alcohol, narcotics or illicit substances
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tine Møller Jørgensen, M.Sc. Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92869</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Vestavia</city>
        <state>Georgia</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pieksämäki</city>
        <zip>76100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Narbonne</city>
        <zip>11108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>H-1212</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>400-103</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>831 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmit</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Slovakia</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>June 26, 2012</lastchanged_date>
  <firstreceived_date>November 10, 2008</firstreceived_date>
  <firstreceived_results_date>November 18, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Public Access to Clinical Trials</name_title>
    <organization>Novo Nordisk A/S</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>48 sites in 8 countries: Canada, Finland, France, Hungary, Slovakia, Republic of Korea, Turkey, and the United States of America (USA)</recruitment_details>
      <pre_assignment_details>Between screening and randomisation, eligible subjects were to continue their usual pre-trial oral anti-diabetic drug (OAD) dose and dosing frequency. Subjects on sulphonylurea (SU) treatment randomised to the insulin detemir group had their SU discontinued</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Comb</title>
          <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
        </group>
        <group group_id="P2">
          <title>Sita</title>
          <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed</title>
              <participants_list>
                <participants group_id="P1" count="107">2 withdrew informed consent. 1 randomised by mistake. 1 non-compliance</participants>
                <participants group_id="P2" count="110">1 non-compliance</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Comb</title>
          <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
        </group>
        <group group_id="B2">
          <title>Sita</title>
          <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="107"/>
                <measurement group_id="B2" value="110"/>
                <measurement group_id="B3" value="217"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.70" spread="9.96"/>
                <measurement group_id="B2" value="57.10" spread="8.41"/>
                <measurement group_id="B3" value="56.90" spread="9.19"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="99"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="68"/>
                <measurement group_id="B2" value="50"/>
                <measurement group_id="B3" value="118"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="96"/>
                <measurement group_id="B2" value="101"/>
                <measurement group_id="B3" value="197"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="83"/>
                <measurement group_id="B2" value="84"/>
                <measurement group_id="B3" value="167"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>HbA1c = glycosylated haemoglobin A1c</description>
          <units>Percent (%) glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8.52" spread="0.65"/>
                <measurement group_id="B2" value="8.52" spread="0.65"/>
                <measurement group_id="B3" value="8.52" spread="0.65"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1.71" spread="0.10"/>
                <measurement group_id="B2" value="1.66" spread="0.09"/>
                <measurement group_id="B3" value="1.68" spread="0.10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="93.1" spread="20.2"/>
                <measurement group_id="B2" value="88.2" spread="19.2"/>
                <measurement group_id="B3" value="90.6" spread="19.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>BMI = Body Mass Index</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="31.79" spread="5.20"/>
                <measurement group_id="B2" value="31.90" spread="5.91"/>
                <measurement group_id="B3" value="31.85" spread="5.56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Stratification</title>
          <description>Previous OAD treatment</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Previous Metformin + Other OAD therapy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="83"/>
                <measurement group_id="B2" value="86"/>
                <measurement group_id="B3" value="169"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Previous Metformin Monotherapy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>FPG</title>
          <description>FPG = Fasting Plasma Glucose</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.69" spread="2.23"/>
                <measurement group_id="B2" value="9.79" spread="2.36"/>
                <measurement group_id="B3" value="9.74" spread="2.29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Diabetes History</title>
          <description>No. of years subject has been diagnosed with diabetes</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.58" spread="5.62"/>
                <measurement group_id="B2" value="9.90" spread="5.65"/>
                <measurement group_id="B3" value="9.74" spread="5.63"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c (Glycosylated Haemoglobin A1c)</title>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>Sample size calculation: Assuming a standard deviation of 1.0 for HbA1c, 100 subjects in each treatment arm would be required to obtain a power of 80% for detecting a HbA1c difference of 0.4%. FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="106"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>HbA1c (Glycosylated Haemoglobin A1c)</title>
            <units>Percent (%) glycosylated haemoglobin</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.08" spread="0.09"/>
                  <measurement group_id="O2" value="7.64" spread="0.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Difference between mean HbA1c in the two treatment arms is equal to zero. Power calculation: Assuming a standard deviation of 1.0 for HbA1c, 100 subjects in each treatment arm would be required to obtain a power of 80% for detecting a HbA1c difference of 0.4%</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0010</p_value>
            <p_value_desc>No corrections to adjust for multiplicity were performed. Statistical significance threshold was p&lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) was used; baseline HbA1c was included as covariate and treatment, stratification and country was included as factors</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving HbA1c Less Than or Equal to 7.0%</title>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="106"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Achieving HbA1c Less Than or Equal to 7.0%</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Target achieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Target not achieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Odds ratio is equal to one.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0010</p_value>
            <p_value_desc>No corrections to adjust for multiplicity were performed. Statistical significance threshold was p&lt;0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Treatment group comparison using logistic regression model incl.treatment,stratification factor, country as fixed effects, baseline HbA1c as covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>6.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving HbA1c Less Than or Equal to 7.0% Without Symptomatic Hypoglycaemia</title>
        <description>Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia</description>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="106"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Achieving HbA1c Less Than or Equal to 7.0% Without Symptomatic Hypoglycaemia</title>
            <description>Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Target achieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Target not achieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="85"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Odds ratio is equal to one.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0080</p_value>
            <p_value_desc>No corrections to adjust for multiplicity were performed. Statistical significance threshold was p&lt;0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Treatment group comparison using logistic regression model incl.treatment,stratification factor, country as fixed effects, baseline HbA1c as covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>4.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving HbA1c Less Than or Equal to 6.5%</title>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="106"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Achieving HbA1c Less Than or Equal to 6.5%</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Target achieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Target not achieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Odds ratio is equal to one.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.063</p_value>
            <p_value_desc>No corrections to adjust for multiplicity were performed. Statistical significance threshold was p&lt;0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Treatment group comparison using logistic regression model incl.treatment,stratification factor, country as fixed effects, baseline HbA1c as covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>5.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving HbA1c Less Than or Equal to 6.5% Without Symptomatic Hypoglycaemia</title>
        <description>Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia</description>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="106"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Achieving HbA1c Less Than or Equal to 6.5% Without Symptomatic Hypoglycaemia</title>
            <description>Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Target achieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Target not achieved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Odds ratio is equal to one.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.135</p_value>
            <p_value_desc>No corrections to adjust for multiplicity were performed. Statistical significance threshold was p&lt;0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>5.37</ci_upper_limit>
            <estimate_desc>Treatment group comparison using logistic regression model incl.treatment,stratification factor, country as fixed effects, baseline HbA1c as covariate</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BMI (Body Mass Index)</title>
        <time_frame>Week 0, Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in BMI (Body Mass Index)</title>
            <units>kg/m^2</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.30" spread="0.15"/>
                  <measurement group_id="O2" value="-0.58" spread="0.14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.121</p_value>
            <p_value_desc>No corrections to adjust for multiplicity were performed. Statistical significance threshold was p&lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>An analysis of covariance (ANCOVA) was used; baseline was included as covariate and treatment, stratification and country was included as factors.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <time_frame>Week 0, Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Body Weight</title>
            <units>kg</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.81" spread="0.44"/>
                  <measurement group_id="O2" value="-1.66" spread="0.42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.109</p_value>
            <p_value_desc>No corrections to adjust for multiplicity were performed. Statistical significance threshold was p&lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>An analysis of covariance (ANCOVA) was used; baseline was included as covariate and treatment, stratification and country was included as factors.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG (Fasting Plasma Glucose)</title>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="106"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>FPG (Fasting Plasma Glucose)</title>
            <units>mmol/L</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.08" spread="0.24"/>
                  <measurement group_id="O2" value="8.52" spread="0.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0010</p_value>
            <p_value_desc>No corrections to adjust for multiplicity were performed. Statistical significance threshold was p&lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>An analysis of covariance (ANCOVA) was used; baseline was included as covariate and treatment, stratification and country was included as factors.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.01</ci_lower_limit>
            <ci_upper_limit>-1.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Episodes</title>
        <description>Overall: All episodes. Minor: Symptomatic, with PG &lt; 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L</description>
        <time_frame>Weeks 0-26</time_frame>
        <safety_issue>No</safety_issue>
        <population>SAS (safety analysis set) is all randomised subjects exposed to at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="110"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hypoglycemic Episodes</title>
            <description>Overall: All episodes. Minor: Symptomatic, with PG &lt; 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L</description>
            <units>episodes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Overall</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Minor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Symptoms Only</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unclassified</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Episodes: Day Time</title>
        <description>Day time: Episodes between 6 pm and 11 am. Overall: All episodes. Minor: Symptomatic, with PG &lt; 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L</description>
        <time_frame>Weeks 0-26</time_frame>
        <safety_issue>No</safety_issue>
        <population>SAS (safety analysis set) is all randomised subjects exposed to at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="110"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hypoglycemic Episodes: Day Time</title>
            <description>Day time: Episodes between 6 pm and 11 am. Overall: All episodes. Minor: Symptomatic, with PG &lt; 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L</description>
            <units>episodes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Overall</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Minor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Symptoms Only</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unclassified</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Episodes: Night Time</title>
        <description>Night time: Episodes between 11 am and 6 pm. Overall: All episodes. Minor: Symptomatic, with PG &lt; 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L</description>
        <time_frame>Weeks 0-26</time_frame>
        <safety_issue>No</safety_issue>
        <population>SAS (safety analysis set) is all randomised subjects exposed to at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="110"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hypoglycemic Episodes: Night Time</title>
            <description>Night time: Episodes between 11 am and 6 pm. Overall: All episodes. Minor: Symptomatic, with PG &lt; 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L</description>
            <units>episodes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Overall</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Minor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Symptoms Only</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unclassified</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-measured 9-point Plasma Glucose Profile</title>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Comb</title>
            <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
          </group>
          <group group_id="O2">
            <title>Sita</title>
            <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Self-measured 9-point Plasma Glucose Profile</title>
            <units>mmol/L</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Before breakfast</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.16" spread="0.20"/>
                  <measurement group_id="O2" value="8.17" spread="0.20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>120 minutes after start of breakfast</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.82" spread="0.28"/>
                  <measurement group_id="O2" value="10.50" spread="0.28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Before Lunch</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.99" spread="0.26"/>
                  <measurement group_id="O2" value="8.01" spread="0.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>120 minutes after start of lunch</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.69" spread="0.28"/>
                  <measurement group_id="O2" value="9.99" spread="0.28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Before dinner</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.85" spread="0.31"/>
                  <measurement group_id="O2" value="8.61" spread="0.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>120 minutes after start of dinner</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.30" spread="0.32"/>
                  <measurement group_id="O2" value="10.20" spread="0.32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bedtime</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.38" spread="0.32"/>
                  <measurement group_id="O2" value="9.42" spread="0.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At 03:00 A.M.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.85" spread="0.26"/>
                  <measurement group_id="O2" value="8.02" spread="0.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Before breakfast the following day</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.07" spread="0.19"/>
                  <measurement group_id="O2" value="7.87" spread="0.19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.50</ci_lower_limit>
            <ci_upper_limit>-1.51</ci_upper_limit>
            <estimate_desc>COMB-SITA Difference. Before breakfast</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.40</ci_lower_limit>
            <ci_upper_limit>-0.89</ci_upper_limit>
            <estimate_desc>COMB-SITA Difference. 120 minutes after start of breakfast</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
            <estimate_desc>COMB-SITA Difference. Before lunch</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.05</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
            <estimate_desc>COMB-SITA Difference. 120 minutes after start of lunch</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.58</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
            <estimate_desc>COMB-SITA Difference. Before dinner</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.75</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
            <estimate_desc>COMB-SITA Difference. 120 minutes after start of dinner</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.88</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
            <estimate_desc>COMB-SITA Difference. Bedtime</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
            <estimate_desc>COMB-SITA Difference. At 03:00 a.m.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.26</ci_lower_limit>
            <ci_upper_limit>-1.34</ci_upper_limit>
            <estimate_desc>COMB-SITA Difference. Before breakfast the following day</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weeks 0-26</time_frame>
      <desc>Safety Analysis Set is all participants treated with trial product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Comb</title>
          <description>Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment</description>
        </group>
        <group group_id="E2">
          <title>Sita</title>
          <description>Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibromatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" events="20" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" events="11" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="76"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="76"/>
                <counts group_id="E2" events="32" subjects_affected="13" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" events="21" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk reserves the right not to release data before passing specified milestones. This includes the right not to release interim results that may later be found to be incorrect. At the end of the trial, one or more manuscripts will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications but will reserve the right to postpone publication and/or communication for a short time to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
